Skip to content
Quant500 - Quantitative Analysis
Search ticker or company...
ES | EN

Company Profile: IDEXX Laboratories, Inc. (IDXX)

IDXX insider trades (13 months) →

$672.04 +0.06% vs. previous close · Market cap $52.94B

Today's multi-factor rank: 233 of 461 · see the ranking

Momentum
3.7/10
Value
3.7/10
Growth
5.0/10
Quality
7.1/10
Multifactor
4.9/10

Market and Valuation

Price & Market

Prev Close Price:$671.64
Open:$662.26
Day's Low:$655.52
Day's High:$681.50
Bid / Ask:-
Market Cap:52.94B
Enterprise Value:53.59B

52-Week Range

52-Week Low:$500.61
52-Week High:$769.98
Current position in 52-week range
52w Low-52w High
50-Day Avg:$536.56
200-Day Avg:$572.42

Volume

Volume Today:1,151,555
Avg Volume (3m):565,096
Avg Volume (10d):667,110
52-Week Change:-6.99%
vs S&P 500, 52 weeks:-
Beta:1.54

Valuation Multiples

P/E (trailing):45.29

Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 2, 2026. The P/E is the price divided by that EPS.

P/E (forward):39.98
PEG Ratio:3.67
Price / Book:28.34
Price / Sales (TTM):11.36
EV / Revenue:11.50
EV / EBITDA:32.13

Dividends

Current yield:-
Annual Dividend Rate:-
Dividend Trailing:$0.00
Yield Trailing:0.00%
5-Year Avg Yield:-
Payout Ratio:0.00%
Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-
Fiscal Year (Next):-

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):4.66B
Gross Profit:2.92B
EBITDA:1.67B
Net Income (TTM):1.18B
Rev Growth (YoY):+9.90%
Earnings Growth (YoY):+17.90%
Quarterly earnings growth (YoY):+15.50%

Margins

Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-

Per Share

EPS Trailing (TTM):$14.84

Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 2, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$16.81
Revenue Per Share:$58.77
Cash Per Share:-
Book Value:$23.71
Last Dividend:-
Ex-Dividend Date:-
Last Split:-

Balance Sheet & Liquidity

Total cash:197.54M
Total Debt:848.88M
Net Debt (Debt - Cash):651.34M
Debt / Equity:45.41%
Current Ratio:1.19
Quick Ratio:0.64

Cash Flows

Operating Cash Flow:1.42B
Free Cash Flow (FCF):1.06B
FCF Yield (FCF / Market Cap):-
Enterprise Value:53.59B
EV / Revenue:11.50
EV / EBITDA:32.13

Profitability

ROE (Return on Equity):68.93%
ROA (Return on Assets):26.54%
P/E (trailing):45.29
P/E (forward):39.98
Price / Book:28.34
PEG Ratio:3.67
52-Week Change:-6.99%
S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$14.84

Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 2, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$16.81
P/E (forward):39.98
PEG Ratio:3.67

Growth and Margins

Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-

Per Share

Revenue Per Share:$58.77
Cash Per Share:-
Book Value:$23.71

Cash Flows (TTM)

Free Cash Flow:1.06B
Operating Cash Flow:1.42B
EBITDA:1.67B
Total Revenue (TTM):4.66B
Net Income (TTM):1.18B
Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter Period Actual EPS Estimated EPS Difference Surprise % Currency

Ownership Structure

Ownership Distribution

% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:78,781,116
Float (free shares):78,543,595
Short interest (shares):1,929,268
Short % of float:-
Short Ratio (days to cover):3.68
Short interest, prior month:-
Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization Report Date % Shares No. Shares Value (USD) Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund Report Date % Shares No. Shares Value (USD) Change %

Recent Insider Trades

Executive / Insider Title Date Action Shares

Options Chain

CALLS

StrikeLastBidAskVol.O.I.IV

PUTS

StrikeLastBidAskVol.O.I.IV

IDEXX Laboratories, Inc. (IDXX) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type Date Official link
8-K2026-11-02View filing ↗
10-Q2026-08-04View filing ↗
SD2026-06-01View filing ↗
8-K2026-05-15View filing ↗
10-Q2026-05-05View filing ↗
ARS2026-03-27View filing ↗
8-K2026-03-26View filing ↗
PRE 14A2026-03-13View filing ↗
10-K2026-02-20View filing ↗
8-K2026-02-13View filing ↗

Company and Executive Profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

General Information

Headquarters:United States
City:Westbrook
Employees:11,000
Sector:Healthcare
Industry:Diagnostics & Research
Website:-

Key Executives

NameTitleAgeTotal pay
Mr. Jonathan J. MazelskyExecutive Chairman643.78M
Mr. Andrew EmersonExecutive VP, CFO & Treasurer421.13M
Mr. Michael J. LaneExecutive VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology571.32M
Dr. Martin Smith Ph.D.Executive Vice President of Global Operations and R&D571.24M
Mr. Michael G. Erickson Ph.D.CEO, President & Director51-
Mr. Bob AsmannSenior Vice President of Global Operations--
Mr. Amit GuptaSenior VP, Chief Digital & Information Officer--
Ms. Sharon E. Underberg J.D.Executive VP, General Counsel, & Corporate Secretary64881,053

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

IDEXX Laboratories, Inc. (IDXX): Quantitative Analysis

IDEXX Laboratories, Inc. (IDXX) — Healthcare — Diagnostics & Research. IDXX is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, IDXX has returned −0.7% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

IDXX ranks 233 of 461 on today's multifactor score, and 31 of the 55 Healthcare companies that score. Its strongest factor is quality (Z 1.28, ranked 17 of 468); its weakest is momentum (Z -0.79, ranked 388 of 494). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

FactorZ-ScoreRank
Multifactor-0.071233 of 461
Momentum-0.788388 of 494 ↓3
Value-0.778470 of 489 ↑2
Quality1.28117 of 468 =
Growth0.003165 of 489

Market data

MetricValue
Price$672.04
Market Cap52.94B
P/E45.29
Revenue (last 12 months)4.66B
Price / book28.34
Book value per share$23.71
52-week range$500.61 – $769.98
Dividend yield0.00%
Beta1.54
Average volume565,096
Shares outstanding78.78M
Short interest (% of float)2.80% (as of Oct 15, 2026)

When does IDXX report earnings? 12 of its last 12, before the open →

What are IDXX insiders doing? 59 transactions filed with the SEC, of them 9 sells, the last one on Sep 4, 2026 →

IDXX latest SEC filings

Filing dates on EDGAR, the SEC's public registry. All IDXX filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about IDEXX Laboratories (IDXX)

When does IDEXX Laboratories report earnings?

IDEXX Laboratories has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Nov 2, 2026). IDXX earnings dates and times, quarter by quarter →

What is IDEXX Laboratories's P/E ratio?

IDEXX Laboratories's P/E (price over earnings per share for the last twelve months) is 45.3 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: IDEXX Laboratories is above its sector median. Healthcare stocks, company by company →

Where does IDEXX Laboratories rank on Quant500?

In the Nov 3, 2026 multi-factor ranking, IDEXX Laboratories ranks 233 of 461, and 31 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking → How it is calculated →

Have IDEXX Laboratories insiders bought or sold shares?

SEC Form 4 shows no open-market purchase of IDEXX Laboratories shares from August 2025 through Nov 3, 2026. The latest sale was on Sep 4, 2026, by a director, for $1.2M. In total, from August 2025 through Nov 3, 2026: 0 purchases and 9 sales by directors, officers and large shareholders. All IDXX insider trades →

What sector is IDEXX Laboratories in, and which index?

IDEXX Laboratories is classified in the Healthcare sector (industry: Diagnostics & Research), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

The model portfolio, weekly in your inbox

Every Saturday, its week in one minute: how it went, the best and the worst, and which insiders bought with their own money. Plus, the day the model is rebuilt, which stocks come in and which go out. A simulation, not advice. At most one email a week, no ads, no account; one-click unsubscribe. Made by one person: Pol Gracia.

A model portfolio with simulated results, not a personalized recommendation. Your email is used for this only: privacy.

S&P 500 market gravity